Niraparib - capsule - 100 mg

DRUG2 trials

Sponsors

Janssen - Cilag International

Conditions

Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)Metastatic Prostate Cancer

Phase 3

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Active, not recruitingCTIS2023-506365-64-00

Janssen - Cilag InternationalDeleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Start: 2020-10-16Target: 211Updated: 2026-01-13

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer

Active, not recruitingCTIS2023-503254-12-00

Janssen - Cilag InternationalMetastatic Prostate Cancer

Start: 2019-03-06Target: 235Updated: 2025-12-09